

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Influenza virus	Sialic acid	<p>Mouse studies suggest multivalent peptides made up of carbohydrate-binding modules could be used to prevent influenza virus infection. Sialic acid-interacting peptides were generated from carbohydrate-binding modules from <i>Streptococcus pneumoniae</i> and <i>Vibrio cholerae</i> sialidase, with or without an oligomerization domain from <i>Pseudomonas aeruginosa</i>. In a mouse model of influenza virus challenge, prophylactic intranasal delivery of a peptide seven days before challenge led to pulmonary expression of IL-1<math>\beta</math>, interferon-<math>\gamma</math> (Ifng; Ifny) and tumor necrosis factor-<math>\alpha</math> (Tnf-<math>\alpha</math>) and enabled survival of all mice. Next steps include testing the peptides in ferret models of influenza infection and conducting toxicology studies.</p>	<p>Patent application filed; available for licensing or partnering from The University of St. Andrews</p> <p><b>Contact:</b> Ewan Chirnside, University of St. Andrews, Fife, U.K. phone: +44 (0)1334 467223 e-mail: <a href="mailto:ec36@st-andrews.ac.uk">ec36@st-andrews.ac.uk</a></p> <p>Connaris, H. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online April 14, 2014; doi:10.1073/pnas.1404205111</p> <p><b>Contact:</b> Robert G. Webster, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: <a href="mailto:robert.webster@stjude.org">robert.webster@stjude.org</a></p>	

*SciBX* 7(18); doi:10.1038/scibx.2014.530  
Published online May 8, 2014